Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Trial Evaluating the Efficacy of Amifostine in Patients With Cancers Receiving Outpatient Dose-intensive Cyclophosphamide, Etoposide, and Cisplatin (DICEP) Chemotherapy

NCT00003269 is registered in ClinicalTrials.gov with Scripps Health as lead sponsor.

NCT NCT00003269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Trial Evaluating the Efficacy of Amifostine in Patients With Cancers Receiving Outpatient Dose-intensive Cyclophosphamide, Etoposide, and Cisplatin (DICEP) Chemotherapy
Lead sponsor
Scripps Health
Phase
Phase 2
Overall status
Completed
Start date
February 28, 1998
Completion date
January 31, 2001
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, drug/agent toxicity by tissue/organ, lung cancer, lymphoma, ovarian cancer, unspecified adult solid tumor, protocol specific